02/04/2026
🌿📄 New research on cannabinoids in prostate cancer
A study in Medical Cannabis and Cannabinoids published in 2026 investigated how cannabinoid therapy impacts disease progression, tumour response, pain, and quality of life in men with prostate cancer.
🔬 Study design:
90 patients were followed for 6 months across three groups: chemotherapy only, cannabis only, and combined therapy. Researchers tracked PSA levels, PET/CT tumour response, and patient-reported outcomes.
📊 Key findings:
• Faster PSA decline was observed in cannabis-containing groups, though final levels were similar across treatments
• Best tumour response occurred with combined cannabis + chemotherapy (over 60% showed remission or reduction)
• No increase in metastasis risk with cannabis use
• Significant improvements in pain and quality of life (mobility, self-care, emotional well-being) in cannabis groups
• A possible dose–response effect suggests higher cannabinoid doses may be linked to better outcomes
💡 Take-home message:
Cannabinoids—especially when used alongside chemotherapy—were associated with better symptom control and improved tumour response indicators, without evidence of harm. However, results are observational and require confirmation in randomized clinical trials.
📖 DOI: 10.1159/000550792
Holistic Healing Dr Gallow Society of Cannabis Clinicians Cannabis Research Council Cancer Playbook Association of Cannabinoid Specialists
Abstract. Introduction: Cannabinoids are increasingly used by cancer patients for symptom relief, yet clinical evidence on their effect in prostate cancer remains limited. This study evaluated the association between cannabinoid therapy and disease activity, pain, and quality of life in men with pro...